Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

113 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunotherapy in cervix cancer.
Attademo L, Tuninetti V, Pisano C, Cecere SC, Di Napoli M, Tambaro R, Valabrega G, Musacchio L, Setola SV, Piccirillo P, Califano D, Spina A, Losito S, Greggi S, Pignata S. Attademo L, et al. Among authors: valabrega g. Cancer Treat Rev. 2020 Nov;90:102088. doi: 10.1016/j.ctrv.2020.102088. Epub 2020 Aug 7. Cancer Treat Rev. 2020. PMID: 32827839 Review.
Trastuzumab-based combination therapy for breast cancer.
Montemurro F, Valabrega G, Aglietta M. Montemurro F, et al. Among authors: valabrega g. Expert Opin Pharmacother. 2004 Jan;5(1):81-96. doi: 10.1517/14656566.5.1.81. Expert Opin Pharmacother. 2004. PMID: 14680438 Review.
Adoptive immunotherapy against ovarian cancer.
Mittica G, Capellero S, Genta S, Cagnazzo C, Aglietta M, Sangiolo D, Valabrega G. Mittica G, et al. Among authors: valabrega g. J Ovarian Res. 2016 May 17;9(1):30. doi: 10.1186/s13048-016-0236-9. J Ovarian Res. 2016. PMID: 27188274 Free PMC article. Review.
Reprogramming T-cells for adoptive immunotherapy of ovarian cancer.
Genta S, Ghisoni E, Giannone G, Mittica G, Valabrega G. Genta S, et al. Among authors: valabrega g. Expert Opin Biol Ther. 2018 Apr;18(4):359-367. doi: 10.1080/14712598.2018.1425679. Epub 2018 Jan 10. Expert Opin Biol Ther. 2018. PMID: 29307234 Review.
PARP Inhibitors in Ovarian Cancer.
Mittica G, Ghisoni E, Giannone G, Genta S, Aglietta M, Sapino A, Valabrega G. Mittica G, et al. Among authors: valabrega g. Recent Pat Anticancer Drug Discov. 2018;13(4):392-410. doi: 10.2174/1574892813666180305165256. Recent Pat Anticancer Drug Discov. 2018. PMID: 29512470 Free article. Review.
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer.
Pignata S, Scambia G, Lorusso D, De Giorgi U, Nicoletto MO, Lauria R, Mosconi AM, Sacco C, Omarini C, Tagliaferri P, Ferrandina G, Cinieri S, Savarese A, Valabrega G, Pisano C, Salutari V, Raspagliesi F, Kopf B, Cecere SC, Amadio G, Maltese G, Di Napoli M, Greggi S, Signoriello S, Daniele G, Sacco A, Losito S, Normanno N, Perrone F, Gallo C, Piccirillo MC; MITO Investigators. Pignata S, et al. Among authors: valabrega g. Gynecol Oncol. 2019 Jun;153(3):535-540. doi: 10.1016/j.ygyno.2019.03.260. Epub 2019 Apr 9. Gynecol Oncol. 2019. PMID: 30979589 Free article. Clinical Trial.
113 results